Clinical Trial Update: Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers [Phase 1]

View source ↗

Summary

Phase 1 study assessing central occupancy of the 5-HT1B receptor by ZOMIG Rapimelt (zolmitriptan) in healthy male volunteers to inform pharmacodynamic propertie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• ZOMIG Rapimelt (zolmitriptan)

Snippet

Sponsor: AstraZeneca | Conditions: Migraine | Phase 1 | Status: COMPLETED